Pulse pressure: An important tool in cardiovascular pharmacology and therapeutics

Drugs

Volumn 63, Issue 10, 2003, Pages 927-932

  Asmar, Roland ^a   Safar, Michel E ^b   Queneau, Patrice ^c  

^a Cardiovascular Institute   (France)

^b HÔPITAL BROUSSAIS   (France)

^c SERVICE DE NEUROLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; INDAPAMIDE; PERINDOPRIL; PLACEBO;

ARTERY TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG TARGETING; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PULSE PRESSURE; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC STUDIES; HUMANS; HYPERTENSION; PULSE;

EID: 0037691607     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363100-00001     Document Type: Review

References (33)

1. Safar ME, London GM. The arterial system in human hypertension. In: Swales JD, editor. Textbook of hypertension. London: Blackwell Scientific, 1994: 85-102
2. Franklin SS, Gustin IV W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation 1997; 96: 308-15
3. Pannier B, Brunel P, El Aroussy W, et al. Pulse pressure and echocardiographic findings in essential hypertension. J Hypertens 1989; 7: 127-32
4. Zanchetti A, Bond MG, Hennig M, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens 1998; 16: 949-61
5. Safar ME. Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Curr Opin Nephrol Hypertens 2001; 10: 257-61
6. Darne B, Girerd X, Safar M, et al. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989; 13: 392-400
7. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease?: the Framingham Heart Study. Circulation 1999; 100: 354-60
8. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC mild hypertension trial. J Hypertens 1999; 17: 1065-72
9. Domanski M, Mitchell G, Pfeffer M, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287: 2677-83
10. Miura K, Dyer AR, Greenland P, et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates: the Chicago Heart Association Detection Project in Industry Study. Hypertension 2001; 38: 232-7
11. Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the Cardiovascular Health Study. Arch Intern Med 2001; 161: 1183-92
12. Blacher J, Gasowski J, Staessen JA, et al. Pulse pressure, not mean pressure, determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085-9
13. Benetos A, Zureik M, Morcet J, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with high cardiovascular mortality. J Am Coll Cardiol 2000; 35: 673-80
14. Blacher J, Guerin A, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal failure. Circulation 1999; 99: 2434-9
15. Laurent S, Boutouyríe P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause mortality in hypertensive patients. Hypertension 2001; 37: 1236-41
16. Meaume S, Rudnichi A, Lynch A, et al. Aortic pulse wave velocity, an independent marker of cardiovascular risk. J Hypertens 2001; 19: 871-7
17. Asmar R, Vol S, Brisac AM, et al. Reference values for clinic pulse pressure in a nonselected population. Am J Hypertens 2001; 14: 415-8
18. Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983-8
19. Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395-401
20. Benetos A, Safar M, Rudnichi A, et al. Pulse pressure: a predictor of long-term cardiovascular mortality n a French male population. Hypertension 1997; 30: 1410-5
21. Benetos A, Rudnichi A, Safar M, et al. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32: 560-4
22. Gerdts E, Papademetriou V, Palmieri V, et al. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am J Cardiol 2002; 89 (4): 399-402
23. Harrington A. The placebo effect: an interdisciplinary exploration. Cambridge: Harvard University Press, 1997
24. Staessen JA, Thijs L, Clement D, et al. Ambulatory pressure decreases on long-term placebo treatment in o der patients with isolated systolic hypertension. J Hypertens 1994; 12: 1035-9
25. Mancia G, Parati G, Ravogli A, et al. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995; 8: 311-5
26. Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens 2001; 14: 546-52
27. Safar ME, Myers MG, Leenen F, et al. Gender influence on the dose-ranging of a low-dose perindopril-indapam de combination in hypertension: effect on systolic and pulse pressure. J Hypertens 2002; 20: 1653-61
28. Asmar RG, Lacourciere Y, on behalf of the Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. J Hypertens 2000; 18: 1683-90
29. Staessen JA, Thijs L, O'Brien ET, et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. Am J Hypertens 2002; 15: 835-43
30. Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as end-point in large-scale intervention trials: the Complior study. J Hypertens 2001; 19: 813-8
31. Safar ME, Rudnichi A, Asmar R. Drug treatment of hypertension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic BP. J Hypertens 2000; 18: 1159-63
32. Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001; 38: 922-6
33. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8